GlobeNewsWire
24 Jun 2026, 23:31 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Revolution Medicines will present data from Phase 1/2 trials for zoldonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC) at the 2026 ESMO Gastrointestinal Cancers Congress. — Clinical data readouts for high-unmet-need cancers like pancreatic ductal adenocarcinoma are primary catalysts for biotech valuation.
+0.60The company is conducting two Phase 3 trials (RASolute 303 and 304) evaluating daraxonrasib for first-line and adjuvant treatment of PDAC. — The progression of assets into Phase 3 demonstrates a path toward potential commercialization and regulatory approval.
+0.40Steve Kelsey, President of R&D, will transition to senior advisor before retiring in January 2027. — Leadership transitions in R&D can create short-term uncertainty regarding the continuity of a company's clinical strategy.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is presenting data from multiple clinical trials at a major medical congress, indicating positive progress in its oncology pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
13h ago
